Our portfolio company, Nucleai announces a strategic partnership to identify, validate and test novel H&E-based biomarkers across Adlai Nortye’s Phase 2 and 3 clinical trials. The collaboration will initially focus on identifying subjects that could derive benefit from Buparlisib treatment in metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) patients and will expand to other indications and clinical trials.
We are excited to partner with Adlai Nortye to bring novel spatial biomarkers to the forefront of drug research and development. The ability to explore, quantify and visualize complex spatial relationships in the tumor microenvironment provides a unique opportunity to transform how therapies are developed, and we look forward to support Adlai Nortye’s mission to disrupt immunotherapy.
said Oscar Puig, VP Translational Medicine and Diagnostics at Nucleai.
Access their full press release here